CA2080462A1 - Therapeutic uses of actin-binding compounds - Google Patents

Therapeutic uses of actin-binding compounds

Info

Publication number
CA2080462A1
CA2080462A1 CA002080462A CA2080462A CA2080462A1 CA 2080462 A1 CA2080462 A1 CA 2080462A1 CA 002080462 A CA002080462 A CA 002080462A CA 2080462 A CA2080462 A CA 2080462A CA 2080462 A1 CA2080462 A1 CA 2080462A1
Authority
CA
Canada
Prior art keywords
actin
therapeutic uses
binding compounds
native
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002080462A
Other languages
French (fr)
Other versions
CA2080462C (en
Inventor
Thomas P. Stossel
Stuart E. Lind
Paul A. Janmey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Thomas P. Stossel
Stuart E. Lind
Paul A. Janmey
The General Hospital Corporation
Brigham And Women's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas P. Stossel, Stuart E. Lind, Paul A. Janmey, The General Hospital Corporation, Brigham And Women's Hospital filed Critical Thomas P. Stossel
Publication of CA2080462A1 publication Critical patent/CA2080462A1/en
Application granted granted Critical
Publication of CA2080462C publication Critical patent/CA2080462C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Abstract

A method for decreasing the concentration of free actin in the plasma of an animal is described which comprises the administration of native and modified actin-binding proteins, and especially the administration of native and modified actin-binding regions of gelsolin. Diagnostic methods for identifying animals in need of such treatment are also described.
CA002080462A 1990-04-11 1991-04-11 Therapeutic uses of actin-binding compounds Expired - Lifetime CA2080462C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50721490A 1990-04-11 1990-04-11
US507,214 1990-04-11
PCT/US1991/002553 WO1991015770A1 (en) 1990-04-11 1991-04-11 Therapeutic uses of actin-binding compounds

Publications (2)

Publication Number Publication Date
CA2080462A1 true CA2080462A1 (en) 1991-10-12
CA2080462C CA2080462C (en) 2004-10-26

Family

ID=24017703

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002080462A Expired - Lifetime CA2080462C (en) 1990-04-11 1991-04-11 Therapeutic uses of actin-binding compounds

Country Status (10)

Country Link
US (2) US5260224A (en)
EP (1) EP0526544B1 (en)
JP (2) JP3616392B2 (en)
AT (1) ATE171625T1 (en)
AU (1) AU663050B2 (en)
CA (1) CA2080462C (en)
DE (1) DE69130289T2 (en)
DK (1) DK0526544T3 (en)
ES (1) ES2124702T3 (en)
WO (1) WO1991015770A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3616392B2 (en) * 1990-04-11 2005-02-02 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド Therapeutic use of actin-binding compounds
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
JP3914272B2 (en) 1993-12-28 2007-05-16 中外製薬株式会社 Gene encoding adseverin
EP0755262A4 (en) * 1994-03-11 1997-05-07 Merck & Co Inc Composition for the treatment of lung disease
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
USRE38392E1 (en) 1996-01-30 2004-01-20 Baylor College Of Medicine Method for identifying metastatic sequences
DE69716460T2 (en) 1996-12-04 2003-06-26 Renovo Ltd Wound healing and treatment of fibrosis
AU7578498A (en) * 1997-05-19 1998-12-11 Chiron Corporation Apoptosis-inducing gelsolin sequences
EP1029048A2 (en) * 1997-11-05 2000-08-23 Baylor College Of Medicine Sequences for targeting metastatic cells
US6545139B1 (en) 1998-03-13 2003-04-08 Baylor College Of Medicine DNA sequence encoding the p99 gene and kits for the detection of neoplasia
US6403766B1 (en) 1999-10-15 2002-06-11 Cornell Research Foundation, Inc. Human actin regulatory proteins and methods for detection, diagnosis and treatment of different stages of carcinogenesis
JP2005508892A (en) * 2001-08-14 2005-04-07 スタテンズ セーラム インスティテュート Purification method for large-scale production of Gc-globulin, substances obtained thereby and their pharmaceutical use
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US7462491B2 (en) * 2002-01-31 2008-12-09 Baylor College Of Medicine Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin
US20030224464A1 (en) * 2002-01-31 2003-12-04 Baylor College Of Medicine Secreted caveolin as a marker for prostate cancer
AU2003226401A1 (en) * 2002-04-16 2003-11-03 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
US7301020B2 (en) * 2003-06-19 2007-11-27 Wisconsin Alumni Research Foundation Macrolide analogs and methods for identifying same
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
ES2464444T3 (en) * 2004-05-12 2014-06-02 The Brigham And Women's Hospital, Inc. Gelsolin for use in the treatment of infections
CA2578478A1 (en) 2004-08-06 2006-02-16 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
US8440622B2 (en) 2006-03-15 2013-05-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
KR101556790B1 (en) 2006-03-15 2015-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. Use of gelsolin to diagnose and treat inflammatory diseases
EP2114460B1 (en) 2007-02-15 2014-07-16 National Jewish Health Compositions for the disruption of biofilms
PL2708603T3 (en) * 2008-01-25 2017-12-29 Beth Israel Deaconess Medical Ct Inc Diagnostic and therapeutic uses of gelsolin in renal failure
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1969388A (en) * 1987-06-19 1989-01-19 Syracuse University Cytochalasin purification methods and compositions
JP3616392B2 (en) * 1990-04-11 2005-02-02 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド Therapeutic use of actin-binding compounds
JPH09315440A (en) * 1996-05-29 1997-12-09 Mitsui Petrochem Ind Ltd Container for wrapping film

Also Published As

Publication number Publication date
DE69130289D1 (en) 1998-11-05
US5508265A (en) 1996-04-16
JP3616392B2 (en) 2005-02-02
DE69130289T2 (en) 1999-06-02
DK0526544T3 (en) 1999-06-21
EP0526544A4 (en) 1993-08-11
ES2124702T3 (en) 1999-02-16
CA2080462C (en) 2004-10-26
AU7751691A (en) 1991-10-30
ATE171625T1 (en) 1998-10-15
US5260224A (en) 1993-11-09
EP0526544B1 (en) 1998-09-30
AU663050B2 (en) 1995-09-28
WO1991015770A1 (en) 1991-10-17
JPH05506034A (en) 1993-09-02
JP2005041881A (en) 2005-02-17
EP0526544A1 (en) 1993-02-10

Similar Documents

Publication Publication Date Title
CA2080462A1 (en) Therapeutic uses of actin-binding compounds
EP0316861A3 (en) Hematology-diagnosis apparatus employing expert system technology
AU4533589A (en) Skin test and test kit for aids
NO960309L (en) Agonists and antagonists of human interleukin-10
DE3650135T2 (en) Protein extraction.
ATE107360T1 (en) EXPRESSION OF HUMAN APOLIPOPROTEINS AI-MILANO IN YEAST.
AU3126484A (en) Protein concentrates from animal blood
DK403384D0 (en) ENTERALLY EFFECTIVE, BIOLOGICALLY ACTIVE PEPTIDE OR PROTEIN AGENTS AND PROCEDURES FOR PRODUCING THEREOF
ATE225125T1 (en) SOLUTION FOR THE PRESERVATION OF ORGANS OR TISSUES OR PARTS THEREOF FROM HUMAN OR ANIMALS
EP0227619A3 (en) New protein and its use
NO892269D0 (en) NON-HYPERGYLYCOSYLED HEPATITY B VIRUS PROTEINS AND EXPRESSION "CASSETTE" AND PROCEDURE FOR THE PREPARATION OF THE PROTEINS.
DK325289A (en) STRONTIUM SALT, METHOD OF PREPARING IT, AND PHARMACEUTICAL AGENTS CONTAINING SALT
CA2139518A1 (en) Antigenic regions of tlp complexes and antibodies against the same
AU8769791A (en) Pharmaceutically active proteins comprising an active protein and an integrinaffinity sequence
EP0436612A4 (en) Amino acid transport proteins, amino acid analogues, assay apparatus, uses thereof for treatment and diagnosis of cancer
DE69002881T2 (en) Peptides and their use.
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
DE68913386D1 (en) Selective enzymatic decomposition of beta-lactoglobulin in whey protein from cow's milk.
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
EP0351790A3 (en) Method for the determination of fructosamine
GB2003887A (en) Isolation of peptides from urine
AU5157493A (en) Protein specific for alzheimer's disease and method of diagnosing alzheimer's disease through detection of the protein
AU4329489A (en) Amino acid transport proteins, amino acid analogues, assay apparatus, uses thereof for treatment and diagnosis of cancer
BR9006746A (en) PHYSIOLOGICALLY ACTIVE PEPTIDE AND REGULATORY AGENT OF CALCIUM METABOLISM
IT8763326V0 (en) MEDICAL PRESIDIUM FOR ELECTROMAGNETOTHERAPY.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry